JOP20200039A1 - مُستحضر صيدلي يشتمل على hcg مأشوب - Google Patents

مُستحضر صيدلي يشتمل على hcg مأشوب

Info

Publication number
JOP20200039A1
JOP20200039A1 JOP/2020/0039A JOP20200039A JOP20200039A1 JO P20200039 A1 JOP20200039 A1 JO P20200039A1 JO P20200039 A JOP20200039 A JO P20200039A JO P20200039 A1 JOP20200039 A1 JO P20200039A1
Authority
JO
Jordan
Prior art keywords
pharmaceutical preparation
recombinant hcg
hcg
recombinant
including recombinant
Prior art date
Application number
JOP/2020/0039A
Other languages
English (en)
Inventor
Cottingham Ian
Plaksin Daniel
Boyd White Richard
Original Assignee
Ferring Int Center Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Center Sa filed Critical Ferring Int Center Sa
Publication of JOP20200039A1 publication Critical patent/JOP20200039A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

يتعلق الاختراع الحالي بمستحضرات تشتمل على hCG ناتج عن عودة الارتباط الجيني ويشار له بالاختصار (r hCG).
JOP/2020/0039A 2009-10-05 2020-02-17 مُستحضر صيدلي يشتمل على hcg مأشوب JOP20200039A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05

Publications (1)

Publication Number Publication Date
JOP20200039A1 true JOP20200039A1 (ar) 2022-10-30

Family

ID=41471027

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0039A JOP20200039A1 (ar) 2009-10-05 2020-02-17 مُستحضر صيدلي يشتمل على hcg مأشوب

Country Status (25)

Country Link
US (5) US8975226B2 (ar)
EP (2) EP2486051B1 (ar)
JP (6) JP6176924B2 (ar)
KR (7) KR102489143B1 (ar)
CN (1) CN107050434B (ar)
AR (2) AR079876A1 (ar)
AU (1) AU2010304922B2 (ar)
BR (1) BR112012007990A2 (ar)
CA (1) CA2776790A1 (ar)
DK (1) DK2486051T3 (ar)
ES (1) ES2798258T3 (ar)
HR (1) HRP20200941T1 (ar)
HU (1) HUE050793T2 (ar)
IL (3) IL218548A (ar)
IN (1) IN2012DN02073A (ar)
JO (1) JOP20200039A1 (ar)
LT (1) LT2486051T (ar)
MX (1) MX2012003951A (ar)
PL (1) PL2486051T3 (ar)
PT (1) PT2486051T (ar)
RS (1) RS60413B1 (ar)
RU (2) RU2588650C2 (ar)
SI (1) SI2486051T1 (ar)
TW (2) TWI532495B (ar)
WO (1) WO2011042688A1 (ar)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
JP6087338B2 (ja) 2011-03-31 2017-03-01 フェリング ベスローテン フェンノートシャップ 医薬製剤
EP2717904A1 (en) * 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
ES2738593T3 (es) 2012-12-10 2020-01-23 Seikagaku Kogyo Co Ltd Factor C recombinante novedoso y método para producir el mismo, y método para medir endotoxina
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
EP3286209B1 (en) * 2015-04-24 2020-11-25 Ferring BV Method of production of gonadotrophin
AU2016282916B2 (en) 2015-06-26 2022-01-20 Ferring B.V. Methods of purification and/or viral inactivation
CN112088011A (zh) * 2018-04-30 2020-12-15 辉凌公司 用于受控的卵巢刺激的组合物
JP2022522566A (ja) * 2020-02-05 2022-04-20 ノバルティス アーゲー ＣＨＯ細胞で発現されたｈｅｔ ＩＬ－１５

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
UA61053C2 (en) * 1995-03-21 2003-11-17 Applied Research Systems Stable liquid pharmaceutical compositions, method for its production and delivery form
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
IL133686A0 (en) 1997-06-25 2001-04-30 Applied Research Systems Glycoprotein hormone analogs, their preparation and use
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
WO2003050286A1 (en) * 2001-10-29 2003-06-19 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
BR0010709B1 (pt) * 1999-05-07 2011-11-29 uso de lh para a produção de um medicamento para induzir a paucifoliculogênese ou unifoliculogênese em mulheres anovulatórias.
ME00296B (me) * 2000-02-22 2011-05-10 Applied Res Systems Ars Holding N V PROCES PREČIŠĆAVANJA hCG I REKOMBINANTNOG hCG PREČIŠĆENOG TOM METODOM
MEP39208A (en) 2001-09-12 2011-02-10 Merck Serono Sa USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
US20050085412A1 (en) * 2001-10-22 2005-04-21 Applied Research Systems Ars Holding N.V. Gonadotrophins for folliculogenesis
CA2465007C (en) * 2001-10-29 2012-01-17 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
KR20050115331A (ko) * 2003-04-01 2005-12-07 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 불임증 포스포디에스터라제의 억제제
SG155777A1 (en) * 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1654353B1 (en) * 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
ATE476666T1 (de) * 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
US8609370B2 (en) * 2004-02-13 2013-12-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
WO2006094810A2 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
DE112006002122B4 (de) 2005-08-15 2016-09-22 Continental Automotive Systems, Inc. ( n. d. Ges. d. Staates Delaware ) Dieselabgas-Kohlenwasserstoff-Dosierventil für Fahrzeuge
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 ｄｎａ칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
US20080248959A1 (en) * 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) * 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
TWI488640B (zh) * 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
JP6087338B2 (ja) * 2011-03-31 2017-03-01 フェリング ベスローテン フェンノートシャップ 医薬製剤
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
EP2486051B1 (en) 2020-03-25
RU2016118236A (ru) 2018-10-29
HRP20200941T1 (hr) 2020-09-18
US11292824B2 (en) 2022-04-05
KR20210141771A (ko) 2021-11-23
LT2486051T (lt) 2020-07-10
US20180030107A1 (en) 2018-02-01
ES2798258T3 (es) 2020-12-10
US10526390B2 (en) 2020-01-07
KR102489143B1 (ko) 2023-01-13
RU2588650C2 (ru) 2016-07-10
RU2016118236A3 (ar) 2019-09-18
EP2486051A1 (en) 2012-08-15
JP2018076296A (ja) 2018-05-17
JP2020000246A (ja) 2020-01-09
CA2776790A1 (en) 2011-04-14
MX2012003951A (es) 2012-05-29
CN102549011A (zh) 2012-07-04
EP3611185A1 (en) 2020-02-19
KR102213154B1 (ko) 2021-02-05
JP2023075144A (ja) 2023-05-30
WO2011042688A1 (en) 2011-04-14
PL2486051T3 (pl) 2020-09-07
US9676835B2 (en) 2017-06-13
JP2013506708A (ja) 2013-02-28
BR112012007990A2 (pt) 2017-07-25
IL250733B (en) 2019-07-31
IL267556A (en) 2019-08-29
KR20210014767A (ko) 2021-02-09
HUE050793T2 (hu) 2021-01-28
TW201113030A (en) 2011-04-16
JP7292153B2 (ja) 2023-06-16
KR20190067256A (ko) 2019-06-14
JP6310440B2 (ja) 2018-04-11
KR101804479B1 (ko) 2017-12-05
DK2486051T3 (da) 2020-06-22
US20140249082A1 (en) 2014-09-04
AU2010304922B2 (en) 2014-11-06
PT2486051T (pt) 2020-06-17
TW201632198A (zh) 2016-09-16
KR101987982B1 (ko) 2019-06-11
AR079876A1 (es) 2012-02-29
US20220340634A1 (en) 2022-10-27
SI2486051T1 (sl) 2020-08-31
RU2724528C2 (ru) 2020-06-23
JP2016074680A (ja) 2016-05-12
IL250733A0 (en) 2017-04-30
JP6580104B2 (ja) 2019-09-25
RU2012112907A (ru) 2013-11-10
KR20170133531A (ko) 2017-12-05
US8975226B2 (en) 2015-03-10
RS60413B1 (sr) 2020-07-31
US20130023476A1 (en) 2013-01-24
AU2010304922A1 (en) 2012-03-29
US20200247863A1 (en) 2020-08-06
TWI532495B (zh) 2016-05-11
AR125991A2 (es) 2023-08-30
KR20190028823A (ko) 2019-03-19
IL218548A (en) 2017-03-30
KR20230012104A (ko) 2023-01-25
JP7196244B2 (ja) 2022-12-26
IN2012DN02073A (ar) 2015-08-21
CN107050434B (zh) 2021-07-27
IL218548A0 (en) 2012-05-31
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
CN107050434A (zh) 2017-08-18
JP2021176867A (ja) 2021-11-11
JP6176924B2 (ja) 2017-08-09

Similar Documents

Publication Publication Date Title
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
MX2013000567A (es) Composiciones farmaceuticas de moduladores de c-met.
EP4302783A3 (en) Modified relaxin polypeptides and their uses
MX2019002979A (es) Formulaciones de anticuerpos.
MX355457B (es) Fsh recombinante que incluye alfa, 2-3- y alfa 2,6-sialilacion.
HK1180601A1 (zh) 抗體製劑
EP2529227A4 (en) IMMUNOGENIC PREPARATIONS BASED ON CYTOMEGALOVIRUS
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
ZA201406381B (en) Levoisovalerylspiramycin i,ii,iii,and preparations,preparations methods and uses thereof
EP3003360A4 (en) High potency pancreatin pharmaceutical compositions
IN2012DN03404A (ar)
EP3157554A4 (en) Compositions, methods and therapies for administering antigen peptide
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
EP2442850A4 (en) Patient hydration system
MY165088A (en) Pharmaceutical compositions comprising alisporivir
EP2515903A4 (en) COMPOUNDS, PREPARATION AND USES THEREOF
WO2012131306A8 (en) Pharmaceutical preparation
MX2015012905A (es) Formulaciones de factor viii recombinantes.
MX2012012489A (es) Preparacion de polipeptidos y sales de los mismos.
JO3497B1 (ar) مستحضر صيدلي يشتمل على hcg مأشوب
MX366768B (es) Tableta orodispersable de sildenafil y metodo para preparar la misma.
JO3808B1 (ar) Fsh ناتج عن عودة الاتحاد الجيني يشتمل على إضافة مجموعة سياليل عند ألفا 2, 3- وألفا
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
AU2010904032A0 (en) Modified relaxin polypeptides
AU2010902059A0 (en) Novel drug delivery system